Kvaliteten af astmabehandling i Danmark: Hvor langt er vi - og hvor langt er patienterne?
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Kvaliteten af astmabehandling i Danmark : Hvor langt er vi - og hvor langt er patienterne? / Ulrik, Charlotte Suppli; Lange, Peter; Plaschke, Peter Paludan; Backer, V.; Søes-Petersen, Ulrik; Harving, Henrik.
In: Ugeskrift for læger, Vol. 170, No. 4, 2008, p. 230-234.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Kvaliteten af astmabehandling i Danmark
T2 - Hvor langt er vi - og hvor langt er patienterne?
AU - Ulrik, Charlotte Suppli
AU - Lange, Peter
AU - Plaschke, Peter Paludan
AU - Backer, V.
AU - Søes-Petersen, Ulrik
AU - Harving, Henrik
PY - 2008
Y1 - 2008
N2 - INTRODUCTION: Despite the availability of safe and effective therapies for asthma, many patients have sub-optimal asthma control. AIM: To assess the current status with regard to the treatment and monitoring of adult asthmatics and to identify factors of importance for compliance with controller therapy. MATERIALS AND METHODS: Based on information from focus group interviews, we developed a questionnaire focusing on knowledge of asthma, compliance and therapy. The participants (n = 509) answered the questionnaire over the Internet. RESULTS: Approximately 70% of patients were treated with inhaled corticosteroids (ICS), whereas 25% were only treated with a short-acting beta2-agonist, 20% of whom had severe asthma. In the preceding year, 46% of patients had their lung function measured. Up to 25% of patients stated that they forgot or deliberately decided not to take their ICS at least twice a week. The most frequent reason for non-compliance was lack of asthma symptoms. Non-compliance was associated with disagreement with the statement that ICS is an essential part of asthma therapy (p<0.002). Self-assessed asthma severity was positively associated with regular scheduled doctor visits (p<0.001) and good compliance (p<0.001). CONCLUSION: The treatment and monitoring of asthma in Denmark is not in accordance with guidelines, e.g. with regard to patient education and the use of spirometry. Non-compliance with controller therapy is frequent, and the reasons seem to be accessible through education of both patients and doctors Udgivelsesdato: 2008/1/21
AB - INTRODUCTION: Despite the availability of safe and effective therapies for asthma, many patients have sub-optimal asthma control. AIM: To assess the current status with regard to the treatment and monitoring of adult asthmatics and to identify factors of importance for compliance with controller therapy. MATERIALS AND METHODS: Based on information from focus group interviews, we developed a questionnaire focusing on knowledge of asthma, compliance and therapy. The participants (n = 509) answered the questionnaire over the Internet. RESULTS: Approximately 70% of patients were treated with inhaled corticosteroids (ICS), whereas 25% were only treated with a short-acting beta2-agonist, 20% of whom had severe asthma. In the preceding year, 46% of patients had their lung function measured. Up to 25% of patients stated that they forgot or deliberately decided not to take their ICS at least twice a week. The most frequent reason for non-compliance was lack of asthma symptoms. Non-compliance was associated with disagreement with the statement that ICS is an essential part of asthma therapy (p<0.002). Self-assessed asthma severity was positively associated with regular scheduled doctor visits (p<0.001) and good compliance (p<0.001). CONCLUSION: The treatment and monitoring of asthma in Denmark is not in accordance with guidelines, e.g. with regard to patient education and the use of spirometry. Non-compliance with controller therapy is frequent, and the reasons seem to be accessible through education of both patients and doctors Udgivelsesdato: 2008/1/21
M3 - Tidsskriftartikel
VL - 170
SP - 230
EP - 234
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 4
ER -
ID: 10906200